Physician profile
Thomas Bouder
NPI 1043203318
$163,177.21
in general payments reported to CMS, 2019-2025
18 companies · $22K in 2025
The $22K reported for 2025 was more than what 97% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $19K · 2021: $35K · 2022: $28K · 2023: $27K · 2024: $16K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $64K · Food and Beverage: $993 · Travel and Lodging: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $64,000.00 |
| Food and Beverage | $993.26 |
| Travel and Lodging | $131.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $147,748.90 | 2019-2025 | Da Vinci Surgical System |
| Ethicon INC. | $14,329.72 | 2019-2020 | |
| Galvanize Therapeutics, INC | $245.01 | 2024-2025 | Aliya System |
| Pulmonx Corporation | $145.75 | 2021-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Genentech USA, INC. | $138.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.91 | 2019 | |
| Covidien LP | $85.20 | 2019 | |
| Auris Health, INC. | $74.12 | 2019 | |
| United Therapeutics Corporation | $70.67 | 2019-2023 | Tyvaso |
| Abbott Laboratories | $51.33 | 2019 | |
| Genzyme Corporation | $48.25 | 2019-2020 | |
| Glaxosmithkline, LLC. | $35.82 | 2019 | |
| Baxter Healthcare | $22.67 | 2021 | |
| Sunovion Pharmaceuticals INC. | $20.76 | 2019 | |
| Abiomed | $18.20 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15.25 | 2020 | |
| Shire North American Group INC | $14.51 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bouder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.